Weight loss drug companies like Novo Nordisk and Eli Lilly are facing challenges as their products, including Ozempic and Wegovy, gain popularity. WeightWatchers CEO sends a memo as the company's stock crashes, possibly influenced by the rise of these medications. The increasing demand for GLP-1 medications, such as Ozempic, is driven by young adults preparing for summer. Legal actions against Novo Nordisk and Eli Lilly focus on social media ads for weight-loss drugs. Geographic and racial disparities exist in accessing semaglutide, the key ingredient in Ozempic and Wegovy.
With the popularity of weight loss drugs soaring, it can seem like everyone is taking one. But new data shows there are stark geographic and racial disparities in who can actually get their hands on semaglutide, the ingredient in Ozempic and Wegovy. https://t.co/yKB2T9kMPu
Ozempic users are demanding answers about why the Therapeutic Goods Administration is warning them to be wary of compounded versions of the drug that has helped them to lose weight and take control of their lives. FULL STORY: https://t.co/r56KOQ1aLs https://t.co/21lMrKVKeG
WeightWatchers stock crashes to an ALL-TIME low - is Ozempic to blame for decline of iconic dieting brand? https://t.co/8wYcCBEvdt https://t.co/KvfUcToe3J
Social media ads for Ozempic and other weight-loss drugs will be a big focus of the lawsuits against Novo Nordisk and Eli Lilly. Here's why: https://t.co/t2JO7rl0xe
With summer months approaching – and pressures that come with showing more skin – more and more young adults are looking to GLP-1 medications, like Ozempic, to get prepped for swimsuit season. https://t.co/8kSB27RvgD https://t.co/4e4jiLjeAL
Lilly weight-loss drug Zepbound new US prescriptions surpass Wegovy for first time https://t.co/kS3RrqrwGp https://t.co/lPX5l879JU
The Lex Newsletter: Living in an Ozempic world https://t.co/CSezowBbvm | opinion
The American Eater Winship is not in the memo, sad! WeightWatchers CEO just sent an internal memo to employees as stock crashes, amid debt concerns, Oprah exit https://t.co/eTstcMTGWc
WeightWatchers CEO memo: "Our business is healthy" WW shares are down 78% on the year. https://t.co/r84vVdhR57
"Clinicians and policy makers must resist the seeming quick fix of GLP-1s." - @CeciConnolly, CEO of @_ACHP, and @samiinkinen, CEO of Virta Health, for @THCBstaff https://t.co/1bmEcIjzjt https://t.co/BXbuSQ1g0D